- GlobeNewswire•12 days agoLeading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)
Liestal, Switzerland, September 13, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that additional data from the pivotal phase III trial (DELOS) demonstrating efficacy of Raxone (idebenone) on inspiratory ...
- GlobeNewswire•17 days agoSanthera's Idebenone (Raxone) Receives Orphan Drug Designation for Duchenne Muscular Dystrophy in Australia
Liestal, Switzerland, September 8, 2016 - Santhera Pharmaceuticals (SWX: SANN), announces today that the Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation (ODD) to idebenone ...
- GlobeNewswire•19 days agoSanthera Announces Financial Results for the First Half Year 2016 and Reports Solid Sales Growth - Company Starts to Build US Operations and Strengthens Board of Directors
Liestal, Switzerland, September 6, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces its financial results for the first half year 2016 and reports solid sales growth. By end of the reporting period ...
SANTHERA N (SANN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
|Day's Range||52.90 - 53.90|
|52wk Range||48.50 - 128.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||29,298|
|Dividend & Yield||N/A (N/A)|